Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.

Iepsen EW, Lundgren J, Dirksen C, Jensen JE, Pedersen O, Hansen T, Madsbad S, Holst JJ, Torekov SS

International journal of obesity (2005)7 Oct 2014Cited by 87 (Europe PMC)

PMID25287751PMCIDPMC4424381DOI10.1038/ijo.2014.177PepBankPUB-25287751

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialMechanism
In obese adults after diet-induced weight loss, liraglutide lowered the rise in soluble leptin receptor by 59% compared with control.
In plain wordsIn obese adults who had lost weight, liraglutide led to a smaller rise in soluble leptin receptor than no liraglutide.
Peptide
Liraglutide
Outcome
DecreaseSoluble leptin receptor increase after 52 weeks
Study
n = 52
Comparator
Control (no liraglutide)
Analysis
Primary
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
1.2 mg per dayAs given in this study (human).
Measurements
Soluble leptin receptor increase
2.1 ng ml(-1)
liraglutide
Soluble leptin receptor increase
5.1 ng ml(-1)
control
Source sentences
Summary
Soluble leptin receptor increase was 59% lower; 2.1±0.7 vs 5.1±0.8 ng ml(-1) (-3.0 (95% confidence interval (CI)=-0.5 to -5.5)), P<0.001
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day).
Report a problemFND-2528775101
02HumanRandomized controlled trialMechanism
In obese adults after diet-induced weight loss, the decrease in free leptin index was 43% smaller with liraglutide than with control.
In plain wordsIn obese adults who had lost weight, free leptin fell less with liraglutide than without it.
Peptide
Liraglutide
Outcome
IncreaseFree leptin index decrease after 52 weeks
Study
n = 52
Comparator
Control (no liraglutide)
Analysis
Primary
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
1.2 mg per dayAs given in this study (human).
Measurements
Free leptin index change
−62
liraglutide
Free leptin index change
−109
control
Source sentences
Summary
free leptin index decrease was 43% smaller; -62±15 vs -109±20 (-47 (95% CI=-11 to -83)), P<0.05 with administration of GLP-1RA compared with control group.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day).
Report a problemFND-2528775102
03HumanRandomized controlled trialEfficacy outcome
In obese adults after diet-induced 12% weight loss, weight did not change significantly over 52 weeks in either the liraglutide or control group.
In plain wordsIn obese adults, the 12% weight loss was kept for 52 weeks in both groups, with and without liraglutide.
Peptide
Liraglutide
Outcome
No significant changeBody weight over the 52-week maintenance period
Study
n = 52
Comparator
Control (no liraglutide)
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg per dayAs given in this study (human).
Source sentences
Summary
The 12% weight loss was successfully maintained in both the groups with no significant change in weight after 52 weeks follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day).
Report a problemFND-2528775103
04HumanRandomized controlled trialEfficacy outcome
In obese adults after diet-induced weight loss, the liraglutide group had a greater weight loss during weight maintenance than control (-2.3 kg).
In plain wordsIn obese adults who had lost weight, liraglutide users lost 2.3 kg more during maintenance than those not given it.
Peptide
Liraglutide
Outcome
DecreaseWeight loss during the maintenance period
Study
n = 52
Comparator
Control (no liraglutide)
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg per dayAs given in this study (human).
Measurements
Weight difference
−2.3 kg
liraglutide vs control
Source sentences
Summary
The GLP-1RA group had greater weight loss during the weight maintenance period (-2.3 kg (95% CI=-0.6 to -4.0))
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day).
Report a problemFND-2528775104
05HumanRandomized controlled trialEfficacy outcome
In obese adults after diet-induced weight loss, the liraglutide group used one fewer meal replacement per day than control.
In plain wordsIn obese adults who had lost weight, liraglutide users needed one fewer low-calorie meal replacement per day than the control group.
Peptide
Liraglutide
Outcome
DecreaseMeal replacements per day
Study
n = 52
Comparator
Control (no liraglutide)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.2 mg per dayAs given in this study (human).
Measurements
Meal replacements per day difference
−1 meals/day
liraglutide vs control
Source sentences
Summary
and had fewer meal replacements per day compared with the control group (minus one meal per day (95% CI=-0.6 to -1)), P<0.001.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day).
Report a problemFND-2528775105
06HumanRandomized controlled trialEfficacy outcome
In obese adults after diet-induced weight loss, fasting glucose fell with liraglutide while it rose in the control group (difference -0.5 mmol/l).
In plain wordsIn obese adults who had lost weight, fasting blood sugar fell with liraglutide but rose in the control group.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose
Study
n = 52
Comparator
Control (no liraglutide)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg per dayAs given in this study (human).
Measurements
Fasting glucose change
−0.2 mmol l(-1)
liraglutide
Fasting glucose change
0.3 mmol l(-1)
control
Source sentences
Summary
Fasting glucose was decreased by an additional -0.2±0.1 mmol l(-1) in the GLP-1RA group in contrast to the control group, where glucose increased 0.3±0.1 mmol l(-1) to the level before weight loss (-0.5mmol l(-1) (95% CI=-0.1 to -0.9)), P<0.005.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day).
Report a problemFND-2528775106
07HumanRandomized controlled trialMechanism
In obese adults after diet-induced weight loss, the meal response of PYY3-36 at week 52 was higher with liraglutide than with control.
In plain wordsIn obese adults who had lost weight, the appetite hormone PYY3-36 rose more after meals with liraglutide than without it.
Peptide
Liraglutide
Outcome
IncreaseMeal response of PYY3-36 at week 52
Study
n = 52
Comparator
Control (no liraglutide)
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
1.2 mg per dayAs given in this study (human).
Source sentences
Summary
Meal response of peptide PYY3-36 was higher at week 52 in the GLP-1RA group compared with the control group, P<0.05.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day).
Report a problemFND-2528775107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT05574439

Young Adults With Early-onset Obesity Treated With Semaglutide

Signe Torekovn = 24630 May 2022 to 1 Apr 2026

Obesity, Adolescent

Trial page ClinicalTrials.govUpdated 8 Jul 2026

Status unknownPhase 4NCT04122716

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Signe Torekovn = 215Sept 2016 to est. Nov 2021

Obesity

Trial page ClinicalTrials.govUpdated 2 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.